Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Info “Usefulness” Needs Further Definition, Pharmacy Groups Say

Executive Summary

FDA should convene an expert panel to refine the definition of "usefulness" for written consumer prescription drug information, the American Society of Health-System Pharmacists recommended
Advertisement

Related Content

Useful Consumer Drug Info Implementation May Be Delayed By FDA Guidance
Useful Consumer Drug Info Implementation May Be Delayed By FDA Guidance
FDA Should Create Oversight Body For Consumer Rx Information, Cmte Says
FDA Should Create Oversight Body For Consumer Rx Information, Cmte Says
Advertisement
UsernamePublicRestriction

Register

PS040221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel